A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions

Cancer Prevention Research

Volumn 1, Issue 5, 2008, Pages 339-348

  Wirth, Lori J ^a   Krane, Jeffrey F ^b   Li, Yi ^a   Othus, Megan ^a   Moran, Amy E ^b   Dorfman, David M ^b   Norris Jr , Charles M ^b   Goguen, Laura ^b   Posner, Marshall R ^a   Haddad, Robert I ^a   Bertagnolli, Monica M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; KI 67 ANTIGEN; ONCOPROTEIN; PROSTAGLANDIN E2; PROTEIN BCL 2; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PILOT STUDY; PRECANCER; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; DINOPROSTONE; FEASIBILITY STUDIES; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOUTH NEOPLASMS; ONCOGENE PROTEIN V-AKT; PILOT PROJECTS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SULFONAMIDES;

EID: 61549101866     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-07-0003     Document Type: Article

References (48)

1. Silverman SJ, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 1984;53:563-8.
2. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:321-9.
3. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998;34: 270-5.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
5. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
6. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit RevOral Biol Med 2003;14:47-62.
7. McCartan B. Malignant transformation of leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:348-9.
8. Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. Int J Oral Maxillofac Surg 1987;16:656-64.
9. Chiesa F, Tradati N, Marazza M, et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993;17:255-61.
10. Schoelch ML, Regezi JA, Dekker NP, et al. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999;35: 333-42.
11. Ha PK, Califano JA. The molecular biology of mucosal field cancerization of the head and neck. Crit RevOral Biol Med 2003;14:363-9.
12. Day GL, Blot WJ, Shore RE, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994;86: 131-7.
13. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10:823-9.
14. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
15. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
16. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98: 441-50.
17. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000;92:977-86.
18. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental β-carotene to prevent second head and neck cancer. Cancer Res 2001; 61:1457-63.
19. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.
20. Wang D, DuBois RN. Prostaglandins and cancer. Gut 2006;55:115-22.
21. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
22. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 2002;8:99-110.
23. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
24. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-92.
25. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; ignaling by cross-talk between two distinct growth factor receptors. FASEB J 2003; 17:1640-7.
26. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
27. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
28. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
29. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
30. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
31. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131:1674-82.
32. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
33. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114:1028-35.
34. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002; 8:314-46.
35. Lage JM, Berkowitz RS, Rice LW, Goldstein DP, Bernstein MR, Weinberg DS. Flow cytometric analysis of DNA content in partial hydatidiform moles with persistent gestational trophoblastic tumor. Obstet Gynecol 1991;77:111-5.
36. Genest DR, Ruiz RE, Weremowicz S, Berkowitz RS, Goldstein DP, Dorfman DM. Do nontriploid partial hydatidiform moles exist? A histologic and flow cytometric reevaluation of nontriploid specimens. J Reprod Med 2002;47:363-8.
37. Moraitis D, Almahmeed T, Weksler B, et al. Tobacco smoke induces cyclooxygenase-2 in epithelial cell lines derived from the human aerodigestive tract. Proc Am Assoc Cancer Res 2002;43:349.
38. Gross ND, Boyle JO, Morrow JD, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005;11:6087-6093.
39. Gallo O, Masini E, Bianchi B, et al. Correlation between cyclooxygenase-2 pathways and tumor angiogenesis in head and neck cancer and its prognosistic significance. Neoplasia 2000;3:53-66.
40. Pannone G, Bufo P, Caiaffa MF, et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopathol Pharmacol 2004; 17:273-82.
41. Shibata M, Kodani I, Osaki M, et al. Cyclooxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol 2005;41:304-12.
42. Nathan CA, LeskovI L, Lin M, et al. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001;92:1888-95.
43. Chang BW, Kim DH, Kowalski DP, et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2004;10:1678-84.
44. Franceschi S, Talamini R, Barra S, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 1990;50:6502-7.
45. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
46. Paulson SK, Hribar JD, Liu NW, et al. Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab Dispo 2000;28: 308-14.
47. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24:296-302.
48. Chen C-C, Sun Y-T, Chen J-J, Chang Y-J. Tumor necrosis factor-α-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and I-κB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 2001;59:493-500.